These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16098836)

  • 21. The hypertriglyceridemic waist phenotype versus the National Cholesterol Education Program-Adult Treatment Panel III and International Diabetes Federation clinical criteria to identify high-risk men with an altered cardiometabolic risk profile.
    Blackburn P; Lemieux I; Alméras N; Bergeron J; Côté M; Tremblay A; Lamarche B; Després JP
    Metabolism; 2009 Aug; 58(8):1123-30. PubMed ID: 19481769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus.
    Alizadeh Dehnavi R; Beishuizen ED; van de Ree MA; Le Cessie S; Huisman MV; Kluft C; Princen HM; Tamsma JT
    Eur J Intern Med; 2008 Mar; 19(2):115-21. PubMed ID: 18249307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do low levels of circulating adiponectin represent a biomarker or just another risk factor for the metabolic syndrome?
    Brooks NL; Moore KS; Clark RD; Perfetti MT; Trent CM; Combs TP
    Diabetes Obes Metab; 2007 May; 9(3):246-58. PubMed ID: 17391150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The metabolic syndrome: Review of current concepts.
    Isezuo SA
    Niger Postgrad Med J; 2006 Sep; 13(3):247-55. PubMed ID: 17278322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome.
    Heald AH; Kaushal K; Siddals KW; Rudenski AS; Anderson SG; Gibson JM
    Exp Clin Endocrinol Diabetes; 2006 Jul; 114(7):371-6. PubMed ID: 16915540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adipokines in diabetes and cardiovascular diseases.
    Kralisch S; Sommer G; Deckert CM; Linke A; Bluher M; Stumvoll M; Fasshauer M
    Minerva Endocrinol; 2007 Sep; 32(3):161-71. PubMed ID: 17912155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Importance of diagnosing and treating the metabolic syndrome in reducing cardiovascular risk.
    Smith SR
    Obesity (Silver Spring); 2006 Jun; 14 Suppl 3():128S-134S. PubMed ID: 16931494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Body iron stores in relation to the metabolic syndrome, glycemic control and complications in female patients with type 2 diabetes.
    Mojiminiyi OA; Marouf R; Abdella NA
    Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):559-66. PubMed ID: 18063352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum adiponectin as a useful marker for metabolic syndrome in type 2 diabetic patients.
    Yun JE; Sull JW; Lee HY; Park E; Kim S; Jo J; Lee SJ; Kim SY; Choi YJ; Jee SH; Huh KB
    Diabetes Metab Res Rev; 2009 Mar; 25(3):259-65. PubMed ID: 19214966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nontraditional cardiovascular risk factors in pediatric metabolic syndrome.
    Retnakaran R; Zinman B; Connelly PW; Harris SB; Hanley AJ
    J Pediatr; 2006 Feb; 148(2):176-82. PubMed ID: 16492425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The SNP276G>T polymorphism in the adiponectin (ACDC) gene is more strongly associated with insulin resistance and cardiovascular disease risk than SNP45T>G in nonobese/nondiabetic Korean men independent of abdominal adiposity and circulating plasma adiponectin.
    Jang Y; Lee JH; Kim OY; Koh SJ; Chae JS; Woo JH; Cho H; Lee JE; Ordovas JM
    Metabolism; 2006 Jan; 55(1):59-66. PubMed ID: 16324920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus.
    Dullaart RP; de Vries R; Sluiter WJ; Voorbij HA
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):221-6. PubMed ID: 18505467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. White adipose tissue and cardiovascular disease.
    Matsuzawa Y
    Best Pract Res Clin Endocrinol Metab; 2005 Dec; 19(4):637-47. PubMed ID: 16311222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients.
    Rosenson RS
    Obesity (Silver Spring); 2009 Mar; 17(3):504-9. PubMed ID: 19023279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammation, the metabolic syndrome and cardiovascular risk.
    Tracy RP
    Int J Clin Pract Suppl; 2003 Mar; (134):10-7. PubMed ID: 12793593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemostasis alterations in metabolic syndrome (review).
    Palomo I; Alarcón M; Moore-Carrasco R; Argilés JM
    Int J Mol Med; 2006 Nov; 18(5):969-74. PubMed ID: 17016629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From hyperglycemia to the risk of cardiovascular disease.
    Leiter LA
    Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of soluble intercellular adhesion molecule-1 with insulin resistance and metabolic syndrome in Taiwanese.
    Hsu LA; Ko YL; Wu S; Teng MS; Chou HH; Chang CJ; Chang PY
    Metabolism; 2009 Jul; 58(7):983-8. PubMed ID: 19394054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelial lipase is increased in vivo by inflammation in humans.
    Badellino KO; Wolfe ML; Reilly MP; Rader DJ
    Circulation; 2008 Feb; 117(5):678-85. PubMed ID: 18212282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.